A clinician may consider an FDA-approved weight-management medicine for adults with obesity or for some adults with overweight who also have weight-related health problems. Semaglutide eligibility depends on the exact product plus medical history, other medicines, pregnancy plans, contraindications, treatment goals and the ability to follow up safely.
This article is for general educational information and is not a substitute for diagnosis, prescribing, dosing or individualized medical advice. Semaglutide is a prescription medicine. Product indications and instructions differ by formulation. Readers should use the exact current prescribing information and speak with a licensed healthcare professional. |
Eligibility starts with the approved indication
NIDDK explains that healthcare professionals commonly use BMI and weight-related health problems when deciding whether prescription weight-management medication may be appropriate. That is a starting point, not the entire evaluation.
The exact FDA-approved product matters. A diabetes-labeled semaglutide product should not be treated as automatically interchangeable with a weight-management-labeled product.
BMI is a screening tool, not a complete health assessment
BMI can help identify weight categories at a population level, but it does not capture body composition, fat distribution, fitness, medications or the full medical picture. A clinician may also consider blood pressure, glucose status, sleep apnea, lipids, cardiovascular disease and other weight-related conditions.
The goal is to understand health risk and treatment benefit, not to reduce a person to one number.
Medical history can change the decision
Current semaglutide labeling includes contraindications and warnings that make medical history essential. A personal or family history of medullary thyroid carcinoma or MEN 2 is particularly important for Wegovy. Prior serious hypersensitivity, pancreatitis history, severe digestive symptoms, gallbladder problems and kidney issues may also affect the discussion.
People who use insulin or medicines that stimulate insulin release may need additional glucose-related monitoring because of hypoglycemia risk.
Pregnancy plans matter
Semaglutide is not a routine weight-loss medicine for pregnancy. Current Wegovy labeling advises discontinuation at least two months before a planned pregnancy because semaglutide has a long half-life.
Anyone who is pregnant, planning pregnancy or breastfeeding should discuss the product-specific risks and recommendations with a qualified clinician.
Readiness for follow-up is part of candidacy
A prescription is not the end of the process. Safe use includes monitoring side effects, nutrition, hydration, treatment response and other medicines. A person who cannot access reliable follow-up may need a different treatment pathway.
Good care also sets realistic goals. The aim is better health and sustainable weight management, not a guaranteed number by a fixed date.
Frequently Asked Questions
What BMI qualifies for weight-loss medication?
Eligibility depends on the product. Clinicians commonly consider obesity, or overweight with weight-related health problems, along with the full medical picture.
Can someone without diabetes use semaglutide for weight management?
Certain semaglutide products are approved for eligible people without diabetes. Product-specific labeling and medical evaluation matter.
Who should not use Wegovy?
Current labeling lists contraindications including a personal or family history of medullary thyroid carcinoma, MEN 2, or prior serious hypersensitivity to semaglutide or product excipients.
Why is medical follow-up needed?
Follow-up helps assess benefit, side effects, hydration, nutrition, drug interactions and whether treatment remains appropriate.
